News

Sarepta Therapeutics Faces Class Action Lawsuit Over Claims

Sarepta Therapeutics Faces Class Action Lawsuit Over Claims

Sarepta Therapeutics Faces Class Action Lawsuit Over Claims

Recently, a class action lawsuit was filed in the U.S. District Court concerning Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This lawsuit brings together investors who purchased or acquired securities during a specific period, signaling potential concerns about the company's practices and statements.

Details of the Lawsuit

Sarepta, known for its focus on genetic medicine, particularly the gene therapy product called ELEVIDYS, faces serious allegations. The claims highlight concerns about misinformation regarding the safety profile and clinical development of this product, which is aimed at treating Duchenne muscular dystrophy.

Allegations Raised

The allegations assert that Sarepta made false and misleading statements during the period of interest, impacting investors' decisions significantly. The specific accusations include:

  • The company misrepresented the safety of ELEVIDYS, disregarding grave risks that were present.
  • It failed to disclose severe adverse events that occurred during clinical trials.
  • Essential information was withheld, leading to an eventual halt in dosing, regulatory scrutiny, and halted shipments.
  • Positive statements about ELEVIDYS’s safety did not have a reasonable foundation.

Key Events Affecting Stock Performance

Several significant incidents have affected Sarepta's stock performance recently, indicating the turbulence investors are experiencing:

  • Incident on March 18, 2025: Sarepta disclosed the tragic news of a patient who passed away while treated with ELEVIDYS. This disclosure led to a sharp drop in shares by 27.44%, bringing the closing price to $73.54.
  • Incident on April 4, 2025: Following a call for a safety review from European regulators, Sarepta halted certain clinical studies. This action resulted in a fall of 7.13% in share value, ending the day at $54.43.
  • Incident on June 15, 2025: Another alarming report indicated a second patient fatality due to acute liver failure. Consequently, shares plummeted by 42.12% to $20.91 as shipment suspensions were announced.
  • Incident on June 24, 2025: The FDA issued a safety communication related to these patient deaths, causing shares to drop by an additional 8.01%, closing at $17.46 on June 25, 2025.

Investors' Next Steps

If you are someone who purchased Sarepta securities during the specified class period and suffered financial losses, it is important to note that there is a deadline approaching. By August 25, 2025, you have the opportunity to request to be appointed as a lead plaintiff in this matter.

Representation by Wolf Haldenstein

Wolf Haldenstein Adler Freeman & Herz LLP is representing those affected in this case. Established in 1888, this firm is dedicated to fighting for investors' rights who believe they have been misled. The firm's rich history in securities litigation means they bring over 125 years of expertise to the table.

Contact Information

For affected investors or those with information to share, it’s crucial to reach out. You can contact Wolf Haldenstein Adler Freeman & Herz LLP directly by calling (800) 575-0735 or (212) 545-4774. Additionally, Gregory Stone serves as the Director of Case and Financial Analysis if you need specific guidance.

Frequently Asked Questions

1. What is the lawsuit about?

The lawsuit centers around allegations that Sarepta Therapeutics misrepresented the safety of their gene therapy product, ELEVIDYS, affecting investor decisions.

2. Who can participate in the class action?

Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, and who suffered financial losses are eligible to participate.

3. What should investors do now?

Affected investors should consider reaching out to legal representation to discuss their options before the August 25, 2025, deadline for appointing a lead plaintiff.

4. Who is Wolf Haldenstein?

Wolf Haldenstein is a law firm with over 125 years of experience in securities litigation, committed to protecting the rights of investors who have faced financial harm.

5. How can I contact Wolf Haldenstein?

You can contact the firm by phone at (800) 575-0735 or (212) 545-4774 to discuss your potential participation in the lawsuit.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hebrew Learning Made Simple: Expert's Structured Guide

Updated Category News Views 0

Cracking the Hebrew Code: A Balanced Guide Ever tried staring down a new language script and felt like you were on a sinking ship? That’s where a lot of folks starting off with Hebrew reading find themselves. It's no sunny stroll through a Greek alphabet park—Hebrew's a whole different ballgame. But Diana Yacobi from Sarah & David’s Read Hebrew Now offers a roadmap...

Continue Reading
Flor de Caña's Green Strategy Wins 2026 Stevie Award

Updated Category News Views 52

Flor de Caña’s Environmental Triumph Seems like when folks think of premium rum, they might wanna start picturing not just smooth sips but a green commitment that runs deep. Flor de Caña has bagged a Stevie Award for their solid 'Net Zero Strategy of the Year.' This ain’t just any award; it's a nod from a respected crowd. A handshake from the business big shots who...

Continue Reading
Timken Maintains Robust Dividend Streak in 2026

Updated Category News Views 0

Timken Keeps Dividend Train Rolling You want to talk consistency? Timken Company just declared its quarterly dividend like clockwork. As a stockholder, that might just be your morning coffee fix before anything else. Notably, Timken's been on the NYSE since 1922, having cranked out 418 consecutive dividend payouts. That's like your grandpa never missing a Sunday golf...

Continue Reading
NYSE Gains Ground with Historic Listings Transfers

Updated Category News Views 130

You'll know it's a topsy-turvy market when hefty firms start switching their stock exchange allegiance. This year, nine noteworthy companies, with a collective market heft of nearly half a trillion dollars, kissed Nasdaq goodbye and nestled into the New York Stock Exchange (NYSE). Now, why would these big shots make the shift, you ask? Let's dive into the nitty-gritty....

Continue Reading
AiPrise Token Sharing Streamlines Compliance Tasks

Updated Category News Views 107

Streamlining the Redundant Chore of Compliance Now, here's something with teeth. AiPrise rolls out its Token Sharing infrastructure, a crafty solution to a common hassle—duplicated compliance work. It's a game changer for financial institutions that find themselves drowning in a sea of repetitive verification tasks. The notion of sharing verified customer data among...

Continue Reading
B2K's Comeback with ECLIPSE Breaks Records

Updated Category News Views 120

Resurgence in the R&B World Well, if you told me B2K would make a grand return and rock the charts after 24 years, I'd have laughed. But it's happening—like a seasoned player making a comeback in overtime. The platinum-selling R&B group B2K launched a new album, 'ECLIPSE,' tied to their 'Boys 4 Life Tour.' The Innovative Marketing Strategy In a move that might just...

Continue Reading
New Intubation Blade: A Potential Game-Changer in EMS

Updated Category News Views 91

Streamlining Emergency Medical Procedures A seasoned paramedic from Norfolk, Virginia, with a knack for solving practical problems, has devised a tool that could revolutionize the emergency medical field: the Dual Purpose Intubation Blade. This innovation is not just about simplifying the intubation process; it’s about taking a massive step forward in how emergency...

Continue Reading
Bybit Expands ByPick Game with Broader Market Reach

Updated Category News Views 24

Bybit Plays the Game of Expansion Step right up to Bybit’s latest offering – ByPick Season 2. Some folks might be scratching their heads about what's shifting in this free-to-play space, but here we are, watching a beast that’s a mix between a carnival game and a hedge fund playpen. No money exchanged, just knowledge on the line. That's right, we're diving into a...

Continue Reading
NJ Water Boosts Fire & EMS Grants to $5K in 2027

Updated Category News Views 70

Water Utility Backs First Responders with Bigger Bucks Listen up, folks. The New Jersey American Water company just threw down the gauntlet with some bold moves for its 2027 Volunteer Fire and EMS Grant Program. They've taken the maximum grant amount from $2,500 to $5,000. Yeah, you heard right. Doubling the pot and starting the application cycle earlier means volunteer...

Continue Reading
Keurig Dr Pepper's $2B Debt Reduction: Strategic Move?

Updated Category News Views 53

Beverage Giant Keurig Dr Pepper Selling Big on Stock In the latest twist from the executive suite of Keurig Dr Pepper (NASDAQ: KDP), they've just pushed out a hefty public offering of nearly 58 million shares at $34.50 a pop. We're talking over a two billion dollar game plan here, folks. The deadline for this brew of equity grabs ends November 16, 2026, if all the...

Continue Reading

Top 5 Most Recently Viewed Articles

Avadel's Board Evaluates Lundbeck's Proposal for Acquisition

Updated Category News Views 195

Avadel Pharmaceuticals Evaluates Lundbeck's Acquisition Proposal Avadel Pharmaceuticals plc (Nasdaq: AVDL) has recently found itself in the corporate spotlight as the company's Board of Directors thoroughly evaluates a new acquisition proposal from H. Lundbeck A/S. This unsolicited proposition has been categorized as a "Company Superior Proposal," which invites intriguing...

Continue Reading
ESET Highlights Growing Threats from AI and NFC Technologies

Updated Category News Views 129

ESET Unveils Critical Trends in Cybersecurity Threats The latest threat landscape trends from ESET Research highlight a significant evolution in AI-driven attacks and the proliferation of NFC threats. These insights are compiled in their recently released H2 2025 Threat Report, detailing cyber threats observed between June and November. Emergence of AI-driven Malware In...

Continue Reading
Insights on Man Group PLC's Stake in American Axle & Manufacturing

Updated Category News Views 145

Understanding Man Group PLC's Disclosure of Interests Man Group PLC, a notable player in the investment sector, has recently made a significant disclosure concerning its position in American Axle & Manufacturing Holdings, Inc. This disclosure, part of regulatory requirements, provides a detailed view of Man Group PLC's holdings. By understanding these positions,...

Continue Reading
Centene Corporation's Second Quarter Results Highlights 2025

Updated Category News Views 663

Financial Overview of Centene Corporation's Second Quarter Centene Corporation (NYSE: CNC) recently shared its financial results for the second quarter of 2025, showing a diluted loss per share of $(0.51) and an adjusted diluted loss per share of $(0.16). The company generated total revenues of $48.7 billion, reflecting the financial complexities of the health care...

Continue Reading
S Hotel Montego Bay Named Top Caribbean Destination in 2024

Updated Category News Views 115

S Hotel Montego Bay Achieves Top Recognition in the Caribbean This year marks a notable achievement for the S Hotel Montego Bay. As revealed by Condé Nast Traveler, this luxurious hotel has clinched the coveted title of the #1 hotel in the Caribbean and Central America for the year 2024. This recognition is particularly significant as it celebrates the ongoing commitment...

Continue Reading